Prophylaxis and treatment of venous thromboembolism in patients with multiple myeloma;Profylaxe a léčba tromboembolické nemoci u pacientů s mnohočetným myelomem

Onkologie

Volumn 5, Issue 3, 2011, Pages 160-162

  Kessler, Petr ^a  

^a Nemocnice Pelh imov   (Czech Republic)

Author keywords

Low molecular weight heparin; Multiple myeloma; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; WARFARIN;

ARTICLE; CANCER REGRESSION; DRUG DOSE REDUCTION; DRUG INDICATION; HEART VALVE PROSTHESIS; HUMAN; LONG TERM CARE; MULTIPLE MYELOMA; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 80855165044     PISSN: 18024475     EISSN: 18035345     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Catovsky D, Ikoku NB, Pitney WR, et al. Thromboembolic complications in myelomatosis. Br Med J 1970; 3: 438-439.
2. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined signifi -cance and multiple myeloma. Blood 2008; 112: 3582-3586.
3. Kristinsson SY, Pfeiff er R, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined signifi cance and multiple myeloma: a populationbased study. Blood 2010; 115: 4991-4998.
4. Libourel EJ, Sonneveld P, van der Holt B, et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010; Jul, 8 116(1): 22-26.
5. Ehrenforth S, Nemes L, Mannhalter C, et al. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V: G1691A. J Thromb Haemost 2004; 2(3): 430-436.
6. Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011; 86(2): 217-220.
7. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
8. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for Venous Thromboembolism. Chest 2011 Mar 24. [Epub ahead of print].
9. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deepvein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98(5): 1614-1615.
10. Bowcock S, Rassam SM, Ward SM, et al. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7(1): 51-53.
11. Kessler P, Pour L, Gregora E, et al. Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma. Klinická onkologie, 2011 v tisku.
12. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003; 21: 16-19.
13. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
14. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
15. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
16. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354(10): 1021-1030.
17. Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and eff ect on survival. Clin Lymphoma 2003; 4(1): 32-35.
18. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010; 115: 1343-1350.
19. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
20. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more eff ective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112: 4445-4451.
21. Avcu F, Ural AU, Cetin T, et al. Eff ects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 2008; 121(4): 567-571.
22. van Marion AM, Auwerda JJ, Lisman T, et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008; 32: 1078-1084.
23. Minnema MC, Fijnheer R, De Groot PG, et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1(3): 445-449.
24. Auwerda JJ, Sonneveld P, de Maat MP, et al. Prothrombotic coagulation abnormalities in patients with newly dia gnosed multiple myeloma. Haematologica 2007; 92(2): 279-280.
25. Zangari M, Saghafi far F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common fi nding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13(3): 187-192.
26. Dunkley S, Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost 2007; 5: 1323-1325.
27. Auwerda JJ, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105(1): 14-20.
28. th Edition). Chest 2008; 133(Suppl 6): 381S-453S.
29. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: eff ects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.
30. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367(9513): 825-831.
31. Klein U, Kosely F, Hillengass J, et al. Eff ective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009; 88(1): 67-71.
32. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106(1): 35-39.
33. Niesvizky R, Martínez-Baños D, Jalbrzikowski J, et al. Prophylactic low-dose aspirin is eff ective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007; 48(12): 2330-2337.
34. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. J Clin Oncol 2011; 29(8): 986-993.
35. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22(2): 414-423.
36. Hájek R, Adam Z, Maisnar V, et al. Doporučení vypracované Českou myelomovou skupinou a Myelomovou sekcí České hematologické společnosti a Slovenskou myelómovou společností pro diagnostiku a léčbu mnohočetného myelomu. Transfuse a hematologie dnes 2009; 15(Suppl 2): 5-80.
37. Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-153.
38. Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; 16(2): CD006650.
39. Kessler P. Profylaxe a léčba tromboembolické nemoci v onkologii. Vnitř Lék 2009; 55(3): 219-222.